Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial

Table 1 Baseline characteristics of patients with rheumatoid arthritis treated with pelubiprofen or celecoxib

Variable	Pelubiprofen (n =77)	Celecoxib (n =68)
Age (mean ± SD, year)	54.3 ± 11.4	54.8 ± 10.8
Female sex, no. (%)	69 (89.6)	62 (91.2)
Disease duration (mean ± SD, month)	100.2 ± 104.2	89.8 ± 88.1
ACR functional class
Class I, no. (%)	25 (32.5)	24 (35.3)
Class II, no. (%)	45 (58.4)	40 (58.8)
Class III, no. (%)	7 (9.1)	4 (5.9)
Class IV, no. (%)	0 (0.0)	0 (0.0)
DMARD use, no. (%)	55 (71.4)	47 (69.1)
Prednisolone use, no. (%)	54 (70.1)	42 (61.8)

ACR, American College of Rheumatology; DMARD, disease-modifying anti-rheumatic drug.
P values were determined using the Student t-test or the χ² test.